| 1 |
Sargramostim With Ipilimumab Containing Therapy in Patients With Solid Tumors |
Solid Tumor|Solid Tumor, Adult |
Biological: Sargramostim|Biological: Ipilimumab-containing therapy |
Partner Therapeutics, Inc. |
Phase 2 |
NCT05284214 |
2024-01-01 |
| 2 |
GDNF Gene Therapy for Multiple System Atrophy |
Multiple System Atrophy |
Biological: AAV2-GDNF gene therapy|Procedure: Sham (Placebo) Surgery |
Brain Neurotherapy Bio, Inc. |
Phase 1 |
NCT04680065 |
2023-10-03 |
| 3 |
Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies |
T-Cell Non-Hodgkin Lymphoma|Acute Myeloid Leukemia|Angioimmunoblastic T-cell Lymphoma|Enteropathy-Associated T-Cell Lymphoma|Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma|Peripheral T Cell Lymphoma|Anaplastic Large Cell Lymphoma|Adult T Cell Leukemia|Adult T Cell Lymphoma|T Cell Prolymphocytic Leukemia|Extranodal NK/T-cell Lymphoma|Transformed Mycosis Fungoides|Sezary Syndrome|Primary Cutaneous Gamma-Delta T-Cell Lymphoma|Hepatosplenic T-cell Lymphoma |
Biological: WU-CART-007 |
Washington University School of Medicine|Wugen, Inc. |
Phase 1 |
NCT05377827 |
2023-07-31 |
| 4 |
ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas |
Low Grade Glioma of Brain |
Drug: PEPIDH1M vaccine + vorasidenib |
Katy Peters, MD, PhD|Servier|Duke University |
Phase 1 |
NCT05609994 |
2023-07-01 |
| 5 |
A Combination Therapy Strategy to Prevent Anti-PD-1 Therapy Resistance in Metastatic Ovarian Cancer Patients |
Ovarian Cancer Stage IV|Ovarian Cancer Stage III|Ovarian Cancer Stage 3 |
Biological: NY-ESO-1 Peptide vaccine|Drug: Nivolumab |
Georgetown University|United States Department of Defense|Bristol-Myers Squibb |
Phase 2 |
NCT05479045 |
2023-07-01 |
| 6 |
A Phase 1 Study of WU-NK-101 in Patients With Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) |
Acute Myeloid Leukemia |
Biological: WU-NK-101 |
Wugen, Inc. |
Phase 1 |
NCT05470140 |
2023-07-01 |
| 7 |
Motixafortide and Natalizumab to Mobilize CD34+ Hematopoietic Stem Cells for Gene Therapies in Sickle Cell Disease (SCD) |
Sickle Cell Disease |
Drug: Motixafortide|Drug: Natalizumab|Procedure: Leukapheresis |
Washington University School of Medicine|BioLineRx, Ltd.|Biogen |
Phase 1 |
NCT05618301 |
2023-06-30 |
| 8 |
SPEARHEAD-3 Pediatric Study |
Synovial Sarcoma|Malignant Peripheral Nerve Sheath Tumor (MPNST)|Neuroblastoma|Osteosarcoma |
Genetic: Afamitresgene autoleucel |
Adaptimmune |
Phase 1|Phase 2 |
NCT05642455 |
2023-06-30 |
| 9 |
A Study of Purified Inactivated Zika Virus Vaccine (PIZV) in Healthy Adults |
Healthy Volunteers |
Biological: Purified Inactivated Zika Virus Vaccine (PIZV)|Other: Placebo |
Takeda |
Phase 2 |
NCT05469802 |
2023-06-01 |
| 10 |
Human Papillomavirus (HPV) Vaccination vs. Placebo for the Treatment of Refractory Cutaneous Warts |
Warts |
Biological: Human Papillomavirus 9-valent Vaccine, Recombinant|Other: Normal Saline |
Western Institute for Veterans Research|University of Utah|Merck Sharp & Dohme LLC |
Phase 2|Phase 3 |
NCT05625633 |
2023-06-01 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.